Head-to-head evidence
PB-718 vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
PB-718
Developed by PegBio
NCT06147544 · Phase 1/2 · completed
The study randomized 36 participants to PB-718 or matched placebo and masked both participants and investigators, but its small sample and safety-focused primary endpoint make it a limited trial for judging clinical benefit. No primary-endpoint results have been posted, so whether the treatment-emergent adverse-event comparison was favorable cannot be determined.
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06077864 · Phase 3 · completed
The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.
Next expected readout: December 2026 · NCT07768813 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PB-718's landscape · survodutide's landscape